BR112019023992A2 - Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado - Google Patents
Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado Download PDFInfo
- Publication number
- BR112019023992A2 BR112019023992A2 BR112019023992-8A BR112019023992A BR112019023992A2 BR 112019023992 A2 BR112019023992 A2 BR 112019023992A2 BR 112019023992 A BR112019023992 A BR 112019023992A BR 112019023992 A2 BR112019023992 A2 BR 112019023992A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- cloning
- pharmaceutical
- hybridoma
- antigen
- Prior art date
Links
- 238000010367 cloning Methods 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 210000004027 cell Anatomy 0.000 title 1
- 239000013599 cloning vector Substances 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 210000004408 hybridoma Anatomy 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 241000282567 Macaca fascicularis Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção refere-se a anticorpos monoclonais de ctla-4, particularmente anticorpos monoclonais humanizados especificamente ligados à ctla-4 com alta afinidade. a presente invenção também fornece anticorpos monoclonais funcionais com reação cruzada à ctla-4 humanas, macacos cinomolgos e camundongos. a presente invenção fornece, ainda, sequências de aminoácidos dos anticorpos da invenção, vetores de clonagem ou expressão, células hospedeiras, e métodos para expressar ou isolar os anticorpos. os epítopos dos anticorpos são identificados. as composições terapêuticas compreendendo os anticorpos da invenção também são fornecidas. a invenção também fornece métodos para o tratamento de cânceres e outras doenças com anticorpos anti-ctla-4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/085134 WO2018209701A1 (en) | 2017-05-19 | 2017-05-19 | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019023992A2 true BR112019023992A2 (pt) | 2020-06-16 |
Family
ID=64273123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019023992-8A BR112019023992A2 (pt) | 2017-05-19 | 2017-05-19 | Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado |
Country Status (13)
Country | Link |
---|---|
US (3) | US11643463B2 (pt) |
EP (1) | EP3625255A4 (pt) |
JP (3) | JP7173993B2 (pt) |
KR (3) | KR102372274B1 (pt) |
AU (1) | AU2017414149A1 (pt) |
BR (1) | BR112019023992A2 (pt) |
CA (1) | CA3060618A1 (pt) |
EA (1) | EA201992755A1 (pt) |
IL (2) | IL270743B1 (pt) |
MX (1) | MX2019013648A (pt) |
PH (1) | PH12019502561A1 (pt) |
TW (2) | TWI793129B (pt) |
WO (1) | WO2018209701A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019006340A (es) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. |
BR112019023992A2 (pt) * | 2017-05-19 | 2020-06-16 | Wuxi Biologics (Shanghai) Co., Ltd. | Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado |
CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
WO2020057610A1 (en) * | 2018-09-20 | 2020-03-26 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific anti-ctla-4/pd-1 polypeptide complexes |
JP2022514702A (ja) | 2018-12-21 | 2022-02-14 | オーエスイー・イミュノセラピューティクス | 二機能性抗pd-1/il-7分子 |
BR112021012536A2 (pt) * | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
KR20210121045A (ko) * | 2018-12-27 | 2021-10-07 | 기가젠, 인코포레이티드 | 항-ctla-4 결합 단백질 및 이의 사용 방법 |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | 包含il-7變體之雙官能分子 |
KR20220166795A (ko) * | 2020-04-13 | 2022-12-19 | 바이오션, 인코포레이티드 | Ctla4에 결합하는 항체 및 이의 용도 |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
WO2022169269A1 (ko) * | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
EP4301467A1 (en) * | 2021-03-01 | 2024-01-10 | Xilio Development, Inc. | Combination of ctla4 and pd1/pdl1 antibodies for treating cancer |
AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
US20240182572A1 (en) | 2021-04-09 | 2024-06-06 | Ose Immunotherapeutics | Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
JP2005529873A (ja) | 2002-04-12 | 2005-10-06 | メダレックス インコーポレイテッド | Ctla−4抗体を使用した治療の方法 |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
CA2602316A1 (en) * | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
EP3375791A1 (en) | 2009-09-30 | 2018-09-19 | Memorial Sloan Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
DK2542590T4 (da) | 2010-03-05 | 2020-07-13 | Univ Johns Hopkins | Sammensætninger og fremgangsmåde til målrettede immunomodulatoriske antistof-fer og fusionproteiner |
GB201103955D0 (en) | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
US9549981B2 (en) | 2011-07-19 | 2017-01-24 | Philogen S.P.A. | Sequential antibody therapy |
US9944689B2 (en) | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
WO2014209804A1 (en) * | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
CA2937370A1 (en) | 2014-01-31 | 2015-08-06 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
US10869926B2 (en) | 2014-07-15 | 2020-12-22 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
CN106999594B (zh) | 2014-11-11 | 2020-08-18 | 免疫医疗有限公司 | 用于治疗瘤形成的治疗组合 |
AU2016219170B2 (en) | 2015-02-13 | 2021-09-09 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CTLA4 |
US10196445B1 (en) | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
EP3288982A1 (en) | 2015-04-28 | 2018-03-07 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
MX2017014699A (es) * | 2015-05-21 | 2018-04-11 | Alligator Bioscience Ab | Polipeptidos novedosos. |
US20160347848A1 (en) | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
US10144779B2 (en) * | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
US10842763B2 (en) | 2015-07-31 | 2020-11-24 | The Johns Hopkins University | Methods for cancer and immunotherapy using prodrugs of glutamine analogs |
JP2019510812A (ja) | 2016-02-26 | 2019-04-18 | イミュネクサス・ピーティーワイ・リミテッド | 多重特異性分子 |
US20190175748A1 (en) | 2016-03-16 | 2019-06-13 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
WO2017175200A1 (en) | 2016-04-08 | 2017-10-12 | The Regents Of The University Of California | Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents |
MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
JP2019527204A (ja) | 2016-07-01 | 2019-09-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抑制性免疫受容体阻害方法および組成物 |
MX2019002925A (es) | 2016-09-15 | 2019-09-05 | Idera Pharmaceuticals Inc | Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. |
WO2018071824A1 (en) | 2016-10-13 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature |
SG11201902857SA (en) | 2016-11-03 | 2019-05-30 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
WO2018148555A1 (en) | 2017-02-09 | 2018-08-16 | Mateon Therapeutics, Inc. | Use of vdas to enhance immunomodulating therapies against tumors |
WO2018156250A1 (en) | 2017-02-21 | 2018-08-30 | Remd Biotherapeutics, Inc. | Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4) |
JP2020508663A (ja) | 2017-02-22 | 2020-03-26 | アレタ・バイオセラピューティクス・インコーポレイテッドAleta Biotherapeutics Inc. | 癌の治療のための組成物及び方法 |
MX2019009660A (es) | 2017-02-28 | 2019-10-02 | Bristol Myers Squibb Co | Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna. |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
BR112019023992A2 (pt) * | 2017-05-19 | 2020-06-16 | Wuxi Biologics (Shanghai) Co., Ltd. | Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado |
MX2019012038A (es) | 2017-05-30 | 2019-11-18 | Bristol Myers Squibb Co | Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico. |
WO2019018841A2 (en) | 2017-07-21 | 2019-01-24 | The Regents Of The University Of Colorado, A Body Corporate | COMPOSITIONS AND METHODS FOR IDENTIFICATION OF COMBINATORIAL IMMUNO-ONCOLOGIC THERAPEUTIC AGENTS |
US11623965B2 (en) | 2017-08-16 | 2023-04-11 | Bristol-Myers Squibb Company | Prodruggable antibodies, prodrugs thereof, and methods of use and making |
EP3707164A4 (en) | 2017-11-07 | 2021-11-24 | Memorial Sloan-Kettering Cancer Center | INHIBITION OF CTLA-4 AND / OR PD-1 FOR THE REGULATION OF T-LYMPHOCYTES |
US20190241660A1 (en) | 2017-12-05 | 2019-08-08 | Intendet Services, Llc | Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer |
US11505831B2 (en) | 2017-12-20 | 2022-11-22 | Dana-Farber Cancer Institute, Inc. | Compositions and methods comprising digital signatures to predict response and resistance to targeted therapy and immunotherapy |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
US20210047410A1 (en) | 2018-02-02 | 2021-02-18 | Oncolmmune, Inc. | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
US20200405890A1 (en) | 2018-02-21 | 2020-12-31 | Cytomx Therapeutics, Inc. | Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof |
EP3765047A4 (en) | 2018-03-13 | 2022-01-12 | Memorial Sloan-Kettering Cancer Center | IMMUNE CHECKPOINT BLOCKADE EXPRESSING ONCOLYTIC VACCINIA VIRUS FOR CANCER IMMUNOTHERAPY |
US20210361734A1 (en) | 2018-03-19 | 2021-11-25 | 9 Meters Biopharma, Inc. | Compositions and methods for potentiating immune checkpoint inhibitor therapy |
CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
GB201810058D0 (en) | 2018-06-19 | 2018-08-08 | Cytovation As | Combination therapy using a peptide |
JP7193628B2 (ja) | 2018-07-06 | 2022-12-20 | 北京天成新脉生物技▲術▼有限公司 | 低adcc/cdc機能性モノクローナル抗体、及びその調製方法と使用 |
CN110898226B (zh) | 2018-07-31 | 2023-05-05 | 苏州亚盛药业有限公司 | Iap抑制剂与免疫检查点分子调节剂的组合用于治疗癌症的方法 |
US20210355219A1 (en) | 2018-09-21 | 2021-11-18 | Harpoon Therapeutics, Inc. | Conditionally activated target-binding molecules |
EP3955960A1 (en) | 2019-04-18 | 2022-02-23 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low ph |
EP3983439A1 (en) | 2019-06-13 | 2022-04-20 | CytomX Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer |
CN114173818A (zh) | 2019-06-13 | 2022-03-11 | 西托姆克斯治疗公司 | 可活化抗pdl1抗体和抗ctla-4抗体在用于治疗癌症的新辅助联合疗法中的用途 |
CN114729045A (zh) | 2019-09-26 | 2022-07-08 | 斯特库比公司 | 对糖基化的ctla-4特异性的抗体及其使用方法 |
TW202114659A (zh) | 2019-10-02 | 2021-04-16 | 德商4Sc製藥公司 | 用於癌症治療之含hdac抑制劑、ctla—4抑制劑及pd—1抑制劑或pd—l1抑制劑之組合 |
-
2017
- 2017-05-19 BR BR112019023992-8A patent/BR112019023992A2/pt unknown
- 2017-05-19 EP EP17909831.4A patent/EP3625255A4/en active Pending
- 2017-05-19 AU AU2017414149A patent/AU2017414149A1/en active Pending
- 2017-05-19 KR KR1020197037477A patent/KR102372274B1/ko active IP Right Grant
- 2017-05-19 EA EA201992755A patent/EA201992755A1/ru unknown
- 2017-05-19 JP JP2019564048A patent/JP7173993B2/ja active Active
- 2017-05-19 WO PCT/CN2017/085134 patent/WO2018209701A1/en active Application Filing
- 2017-05-19 MX MX2019013648A patent/MX2019013648A/es unknown
- 2017-05-19 US US16/614,777 patent/US11643463B2/en active Active
- 2017-05-19 KR KR1020237012448A patent/KR20230053001A/ko not_active Application Discontinuation
- 2017-05-19 KR KR1020227007058A patent/KR102522693B1/ko active IP Right Grant
- 2017-05-19 CA CA3060618A patent/CA3060618A1/en active Pending
- 2017-05-19 IL IL270743A patent/IL270743B1/en unknown
- 2017-05-19 IL IL312337A patent/IL312337A/en unknown
-
2018
- 2018-05-18 TW TW107117009A patent/TWI793129B/zh active
- 2018-05-18 TW TW112103167A patent/TW202321302A/zh unknown
-
2019
- 2019-11-15 PH PH12019502561A patent/PH12019502561A1/en unknown
-
2020
- 2020-08-06 US US16/987,334 patent/US11078281B2/en active Active
-
2021
- 2021-11-12 JP JP2021184687A patent/JP2022024054A/ja not_active Withdrawn
-
2023
- 2023-03-21 US US18/187,475 patent/US20230382994A1/en active Pending
- 2023-09-29 JP JP2023170002A patent/JP2023182705A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230382994A1 (en) | 2023-11-30 |
EA201992755A1 (ru) | 2020-04-22 |
TW201900679A (zh) | 2019-01-01 |
EP3625255A4 (en) | 2021-02-24 |
KR20230053001A (ko) | 2023-04-20 |
US11078281B2 (en) | 2021-08-03 |
KR20220034920A (ko) | 2022-03-18 |
CA3060618A1 (en) | 2018-11-22 |
WO2018209701A1 (en) | 2018-11-22 |
PH12019502561A1 (en) | 2021-01-25 |
US20210040214A1 (en) | 2021-02-11 |
AU2017414149A1 (en) | 2019-11-07 |
TW202321302A (zh) | 2023-06-01 |
US20200277377A1 (en) | 2020-09-03 |
KR102522693B1 (ko) | 2023-04-17 |
IL312337A (en) | 2024-06-01 |
EP3625255A1 (en) | 2020-03-25 |
JP7173993B2 (ja) | 2022-11-17 |
JP2022024054A (ja) | 2022-02-08 |
KR20200061320A (ko) | 2020-06-02 |
IL270743A (en) | 2020-01-30 |
TWI793129B (zh) | 2023-02-21 |
KR102372274B1 (ko) | 2022-03-08 |
IL270743B1 (en) | 2024-05-01 |
JP2023182705A (ja) | 2023-12-26 |
MX2019013648A (es) | 2021-01-08 |
JP2020520655A (ja) | 2020-07-16 |
US11643463B2 (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019023992A2 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado | |
HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
CO2021006248A2 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
HRP20201191T1 (hr) | Mutirani multispecifični fab fragmenti antitijela | |
EA201990781A1 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
BRPI0717363B8 (pt) | imunoglobina humanizada que liga especificamente cd20, composição, vetor recombinante, métodos para obter uma célula hospedeira, de produção de uma imunoglobina que liga especificamente cd20, in viro para inibir o crescimento ou diferenciação de uma célula b humana normal e usos de imunoglobina e de uma quantidade efetiva de imunoglobina | |
EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
JP7209464B2 (ja) | ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体 | |
RU2018139811A (ru) | Мультиспецифические антигенсвязывающие конструкции, нацеливающие иммунотерапевтические средства | |
FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
CN116769035A (zh) | 抗4-1bb抗体及其制备和使用方法 | |
BRPI0607757A2 (pt) | anticorpo, composição, imunoconjugado, molécula bi-especìfica, molécula de ácido nucleico isolado, vetor de expressão, célula hospedeira, hibridoma, método para preparar um anticorpo anti-psma, e, usos de um anticorpo, ou porção de ligação a antìgeno do mesmo | |
RU2018102526A (ru) | Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение | |
US10941196B2 (en) | Anti-TNF-α fully human monoclonal antibodies with low immunogenicity and application thereof | |
AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
BR112015010046A2 (pt) | Proteínas de ligação a antígeno ou um fragmento de ligação a antígeno da mesma e seu método de produção, vetor, célula hospedeira de microrganismo transgênico, imunoconjugado e seu uso, composição farmacêutica e hibridoma murino | |
BR112022001902A2 (pt) | Proteína biespecífica de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica e método para a produção da proteína biespecífica de ligação ao antígeno | |
WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
MX2022011951A (es) | Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos. | |
MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
BR112018008983A2 (pt) | moléculas de ligação específicas para asct2 e seus usos | |
BR112022000628A2 (pt) | Anticorpos anti-tigit e aplicação dos mesmos | |
MX2021010281A (es) | Proteinas de enlace a antigenos que se enlazan al bcma. | |
BR112022020256A2 (pt) | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |